Objectives and Background

This study investigates genetic and functional abnormalities of mast cells, which drive allergic responses and can, in some cases, progress to neoplasia. Mast cells are immune cells that release inflammatory mediators such as histamine, triggering acute allergic symptoms; understanding their regulatory mechanisms can contribute to diagnostic and therapeutic innovation. A government‑led large‑scale screening focuses on long‑term data accumulation, contrasting with the shorter‑term focus of private companies.

Population and Design

The study commenced in November 2010 and enrolled up to 1,000 participants over five years, comprising one‑third patients and two‑thirds relatives. Ages from 1 to 80 years were eligible, allowing comprehensive capture of age‑specific phenotypes of hereditary disorders. The investigation is observational with no therapeutic intervention, focusing on genetic and functional analyses of blood samples.

Data Collection and Utilization

Participants complete clinical questionnaires and provide blood (5–30 ml) for assessment of genetic variants and mast cell growth and activity. Collected specimens serve as a biorepository that can support not only the current study but also future biomarker development and novel drug target discovery. Preliminary results are reviewed at 12 months, and subjects of continued interest are invited to participate for an additional year.

Anticipated Impact and Differentiation

This large‑scale genetic screening goes beyond conventional allergy therapies that primarily address symptoms, by identifying causal genetic variants and enabling the development of personalized treatments. Data on rare hereditary mast cell disorders—an area with few approved therapies—will provide essential foundational material for biotech companies building new drug pipelines. Moreover, as a government‑driven initiative, the study offers high data accessibility and transparency, expected to generate broad impact across academia and industry.